5760nok
7,9 %
Date:2026-07-09Time:18:00:00Latest report:Q4-2025List:Oslo BorsTicker:ONCIN
Market Cap:258 mnokEnterprise Value:80 mnokNet Sales:23,0 mnokEarnings:-155,1 mnokEmployees:0ISIN:NO0013711713

Ratios

10-year key figure history for Oncoinvent turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Oncoinvent with index and moving average MA50 and MA200.

Stockprice:57,60
MA50:47,50
MA200:61,36
Price/MA200:-6,1 %
RSI (14):74,2
Price/MA50:21,3 %

Description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Biotechnology